statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

NextCure appoints Rakesh Dixit to Scientific Advisory  Board

BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

NextCure, Inc. (NASDAQ:NXTC  Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 839,700 shares, an...

NextCure, Inc. (NASDAQ:NXTC) Short Interest Update

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
NXTC stock results show that NextCure beat analyst estimates for earnings per share the fourth quarter of 2023.
The post NXTC Stock...

NXTC Stock Earnings: NextCure Beats EPS for Q4 2023

Prioritizing and focusing on highest-value opportunities NC410 (ovarian and CRC) and LNCB74 (B7-H4 ADC)Based on early evidence of clinical activity with NC410 combo, expanding ovarian and CRC cohorts...

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

NextCure's treatment of AML granted FDA orphan designation

NextCure publishes preclinical data on function of FLRT3

BELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

NextCure presents preclinical VSTM-1 data

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Watchers	1,764
52-Wk Low	$0.98
52-Wk High	$2.57

Volume	79,187.00
52-Wk High	$2.57
52-Wk Low	$0.98

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.39	--	--	N/A
Q1'24	-$0.46	-$0.61	-32.61%	MISSED
Q4'23	-$0.54	-$0.52	4.29%	BEAT
Q3'23	-$0.66	-$0.51	22.43%	BEAT
Q2'23	-$0.55	-$0.64	-15.82%	MISSED

NXTC Nextcure Inc

About

Feed

News

Sentiment

Earnings

Fundamentals